FDA issues draft guidance on marketing submissions for AI-enabled medical devices

The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.